Highlights -the frequency of epilepsy is 4.5 times higher than in the general population.
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Introduction
Multiple sclerosis is a chronic inflammatory disease of the central nervous system, characterized by focal white matter lesions, but both deep and cortical grey matter is also involved [1] [2] [3] .
A review of 29 previously published clinical series found the mean prevalence of epilepsy among MS patient to be 2.3%, [3] [4] [5] [6] times that in the general adult population [4] . In the general Norwegian population the prevalence of epilepsy is about 0.7% [5] [6] [7] .
Epilepsy has previously been reported in 3.2 to 3.6 % of the Norwegian MS patients [8, 9] . The cause of the increased occurrence of epilepsy among patients with MS is unknown [4] , but it is reasonable to assume an epileptogenic role of cortical lesions [10] .
The aim of the study was to identify and describe the patients with epilepsy in a welldefined MS-population [11] of northern Norway at prevalence date January 1, 2010.
Methods
This was a retrospective cross-sectional epidemiological study based on patient records of all known MS patients living in Nordland County, Northern Norway at prevalence point.
Nordland County is situated between latitude 64°56' N and 69°20' N, and is covering a total area of 38456 km 2 . The population was 236 271 (118537 men, 117734 women) at January 1, 2010.
There is only one neurological department in the county, at the Nordland Hospital in Bodø, serving the majority of the population, but there are also two neurological outpatient services at the hospitals in Mosjøen (Helgeland) and Stokmarknes (Vesterålen). We had full access to the MS-patients medical files. The medical records were consecutively written as electronic files from 1992, and older documents are scanned and added to the electronic files.
In a previous population study [11] (1.4 %) with unknown disease course. In the present study, we were able to classify these six patients as having RRMS at onset. In the present study we also ascertained the transformation from RRMS at onset to secondary progressive MS (SPMS).
The medical files were scrutinized to identify seizures and epilepsy. The diagnosis of epilepsy was set in accordance with the 1989 criteria of the International League Against Epilepsy [14] . Active epilepsy was defined as use of antiepileptic drugs at prevalence point or seizures within the last 5 years [15] . Seizures were classified according to the criteria of the International League Against Epilepsy from 1981 [16] .
We classified the epilepsy as focal or not, based on the described seizure semiology and 
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Results
The Table 1 shows demographics and clinical characteristics of these patients.
Simple partial seizure was noted in four patients, and in one of these there was also evidence of complex partial seizures. In total, we classified three patients with complex partial seizures. In addition, one patient was reported to have slurred speech prior to a generalized seizure, and another reported feeling "strange" prior to generalized convulsions. Generalized seizures were reported in 11 patients, of which 10 had convulsive and one had nonconvulsive seizures. In two patients, eye deviation was noted during a generalized seizure. One of these patients also had a post-ictal transient hemiparesis (Todd's paresis) ipsilateral to the eye deviation.
All patients with MS and epilepsy had at least one electroencephalogram (EEG), and in total 69 EEG-recordings were registered. There were epileptiform discharges in 17 (Fig1), focal slow activity without epileptiform discharges in 20, diffuse slow activity without epileptiform discharges in 14, and 18 recordings were normal.
With the reported seizure semiology and the EEG findings combined, focal epilepsy was registered on at least one occasion in 12 of the 14 patients (86%) with active epilepsy.
Status epilepticus was reported in five (36%) of the patients. Four had generalized clonic seizures. Gaze deviation was noted in two of these. One patient had a simple partial status epilepticus with prolonged convulsions in the right part of her body. There were no fatal cases of status epilepticus.
One patient experienced a seizure before other symptoms of MS. Another patient was registered with a seizure as the onset symptom, and a third patient experienced her first seizure the same year as the first symptom of MS, but 10 years prior to the MS diagnosis. The remaining 11 patients got their first epileptic seizure after the diagnoses of MS.
The mean age at prevalence day was 56. Four of the 14 patients with active epilepsy had PPMS and the remaining 10 had RRMS at onset, of whom seven had converted to SPMS. The conversion from RRMS to SPMS was significantly higher for those with active epilepsy than in those without epilepsy (p=0.02). Three of the seven (43%) had converted to SPMS before, and four of seven (57%) after they got epilepsy.
Five (36%) of the patients with active epilepsy had been, or were exposed to immune modulating drugs for MS. Only one had used it (interferon beta-1b) at the time of the first epileptic seizure. Two other had used interferon beta-1b later, one had used interferon beta-1a and one had used glatiramer acetate. Three patients had immunmodulating therapy at prevalence point. Table 1 shows the antiepileptic medication in use at prevalence point. Ten patients (72%) received monotherapy, two (14%) received two anti-epileptic drugs, and two (14%) were untreated.
Discussion
On January 1 2010, 3.2 % of MS patients in Nordland County had active epilepsy. That is approximately 4.5 times higher than reported in the general Norwegian population.
Our finding is in accordance with two previous Norwegian studies of similar sizes [8, 9] .
The findings are also comparable to international reports [18] .
A prevalence study of 1717 subjects with active epilepsy in a general Norwegian population, reported that 64% had focal onset seizures [7] . Our results showing that 86% of the patients with MS had focal epilepsy, confirm a previous Norwegian study where all MS patients had a focal epilepsy [8] . The finding indicates that focal brain pathology in MS is the main cause of the comorbid EP. White matter lesions, with or without inflammation and edema, may irritate the cortex resulting in seizures. A study from France reported subcortical involvement in all of their 17 patients with MS and epilepsy [19] . Furthermore, it is an increasing concern that MS is not only a white matter disease, but that is also affects the gray matter in the cerebral cortex [1] [2] [3] .
Increased number of both juxtacortical and cortical lesions in MS patients with comorbid epilepsy has been reported [20] . In MS-patients with epilepsy the cerebral cortex has shown signs of more extensive inflammation when compared to the cortex of MS patients without epilepsy matched for sex, age, disease duration and EDSS [21] . In this study by Calabrese et al, intracortical lesions were found in 90 % of patients with RRMS and epilepsy, but only in 48 % RRMS without epilepsy. Furthermore, the mean number of intracortical lesions was 6.8 ±8.3 in RRMS patients with epilepsy, and 1.5 ±2.4 in the control group.
Although epilepsy can be the first symptom of MS [22] , in the present study only one of support the idea that the risk of epilepsy in MS increases with disease duration and number of lesions.
However, excluding the sole patient who got epilepsy before MS, we find that the delay from MS to epilepsy ranges from 0 to 30 years. At prevalence date there was a large span in severity of MS, with EDSS ranging from 0 to 9.5. These findings are in accordance with previous reports. Among 21 MS patients with epileptic seizures, there seemed to be no clear correlation between the severity of MS and epilepsy [23] . In another study of 40 MS patients with comorbid epilepsy, no relationship was found between the frequency of seizures and the severity of MS [24] . In yet another study of 13 MS patients with epilepsy, EDSS ranged from 1.0 to 8.0, and the seizures started 1-23 years after onset of MS [25] . It therefore seems that EP is independent on the disability level, and can evolve at any time during the course of MS. It is possible that epilepsy in the early stage of MS is caused mainly by inflammation, and that epilepsy in the later stage is caused more by neurodegeneration. According to Spatt, most MS patients with comorbid seizures could be placed in one of two groups. They could either have symptomatic seizures associated with MS onset or relapse, usually without recurrent seizures, or they could have chronic epilepsy associated with progressive cognitive involvement and increasing disability [26] .
It has been reported that MS patients with epilepsy are younger than those without epilepsy [27, 28] . In our study, the mean age of patients with epilepsy was not significantly different from the mean age in the cohort of patients without epilepsy, neither at prevalence point nor at time of diagnosis of MS (table 2) .
It has also been reported that MS-patients with epilepsy have a higher progression rate of cortical pathology than MS controls, and also have a more rapid cognitive decline [29] . Furthermore, the time to reach a certain invalidity (score 6 at Kurtzke Disability Status Scale) has also been reported to be shorter in MS patients with epilepsy than in MS patients without epilepsy [27] . In our population, 7 of 10 (70%) of the patients with RRMS at onset had converted to SPMS. This was significantly higher (p=0.02) than in the RRMS group without active epilepsy, where only 35 % had converted to SPMS.
The finding may imply that the patients with active epilepsy have a more aggressive form of MS. Most untreated RRMS patients will eventually convert to SPMS with time, around 80% within 20 years [30] . Disease duration may therefore be a confounder. In the present study the mean disease duration was about 4.5 years longer for the group of RRMS with active epilepsy than in those without epilepsy. However, a longer mean disease duration in the group with epilepsy is expected, as they, by definition, must have developed both MS and epilepsy, and the first seizures may occur many years after the diagnosis of MS. On the other hand, it is also possible that patients with SPMS are more likely to develop epilepsy. Our figures do not allow for a conclusion on this matter, as 3 of 7 had converted to SPMS before they got epilepsy and 4 of 7 after. If we add the four PPMS patients with active epilepsy, a total of 11 of 14 (78.6%) of the patients had progressive MS. This is similar to another small study that reported the progressive form of MS in 6 of 8 (75 %) of the patients with epilepsy [31] .
It has been hypothesized that interferon beta could have proconvulsive properties due to metabolic interference with antiepileptic drugs or due to a direct neurotoxic effect [32].
This view is not supported by our study, where the majority of the patients (64%) had never used immune modulating medication, and where only one used interferon beta at the time of the first epileptic seizure. Secondary progressive MS was noted in 43% of patients prior to their diagnosis of epilepsy, and that may explain why so few patients with epilepsy was not on MS-therapy.
Status epilepticus was reported in 36% of the patients. Because of the risk of new seizures and status epilepticus, the importance of early use of antiepileptic drugs in MS patients with epilepsy has been emphasized [8] . Others report that the majority of MS patients with epilepsy responded well to first line antiepileptic therapy [31] . In the present study, 10 of 14 patients had monotherapy for epilepsy and two had no antiepileptic treatment. This indicates well-managed epilepsy with good seizure control.
A strength of our study is that the MS population is well defined, and that we have access to longitudinal clinical information from electronic patient records. Patients with MS consult a neurologist on a regular basis, and any event that raises the suspicion of epilepsy would most likely be further examined. In general, patients with a seizure will be referred for diagnostic work-up. The prevalence of epilepsy among MS patients reported in the present study will therefore probably be close to the real prevalence in the MS population. The diagnostic accuracy of epilepsy may however be cause for concern, especially among MS patients where there could be many different paroxysmal symptoms. The differential diagnosis include muscle cramps, dystonia and other involuntary movements in addition to syncope, hypoglycemia, and seizures not fulfilling the criteria for epilepsy. The medical records were scrutinized with this in mind, and if we were in doubt the case was not included in this study. Three of the patients with RRMS at onset have unknown course. y = years, SD = standard deviation, PPMS = primary progressive multiple sclerosis, RRMS = relapsing-remitting multiple sclerosis; SPMS = secondary progressive multiple sclerosis A highly disabled 53 year-old woman, diagnosed with primary progressive multiple sclerosis three years earlier, was brought to the hospital due to three generalized seizures and prolonged confusion. Viral encephalitis was suspected, but investigations, including CSF-analyses, were negative. She recovered and was treated with oxcarbazepine.
Conclusion
a. EEG recording on the day of admission showing spike discharges on the left in the fronto-temporal region.
b. The coronal slice of a FLAIR MRI obtained the same day as the EEG showing multifocal areas of high signal intensity in the white matter, but there is also increased signal in the left insular cortex which is not typical for MS.
